排序方式: 共有62条查询结果,搜索用时 15 毫秒
1.
2.
K. Höffken Kh. Merkle M. Schönfelder G. Anger M. Brandtner K. Ridwelski S. Seeber 《Journal of cancer research and clinical oncology》1998,124(11):627-632
A phase II pilot study of bendamustine as salvage treatment in patients with advanced breast cancer was performed to determine
the objective response rates and make further observations on the toxicity of this drug. A group of 37 patients, pretreated
with chemotherapy for advanced disease, entered the trial. Treatment consisted of 150 mg/m2 bendamustine on days 1 and 2 of a 4-week treatment course. Patients continued to receive treatment until complete remission
and then two further courses, until tumour progression or unacceptable toxicity ensued. A total of 36 patients received at
least one treatment course and were assessable for toxicity; 33 patients were evaluable for treatment results. Dose-limiting
grade 3 and 4 WHO toxicity occurred in 5 and 3 patients respectively; 27% of patients entered complete or partial tumour remission.
The median time to tumour progression was 2 months with a range of 1–14 months. The efficacy of bendamustine was apparently
independent of pretreatment with anthracyclines, suggesting a lack of cross-resistance between bendamustine and anthracyclines.
It can be concluded that bendamustine in the dose and application schedule used here is active in the salvage therapy of women
with advanced breast cancer. The toxicity was acceptable. Future studies have to confirm the data of this pilot trial and
to define the role of bendamustine in the combination chemotherapy of metastatic breast cancer that has been suggested by
previous trials.
Received: 9 April 1998 / Accepted: 24 June 1998 相似文献
3.
Tarig Mohammed Abkur Mamoun Saeed Saad Zeinalabdin Ahmed Ryan McArthur Maeve Leahy Hilary O'Leary Denis O'Keeffe 《Clinical Case Reports》2015,3(4):255-259
The decision for PJP prophylaxis depends on a physician's evaluation of multiple variables. The high rate of PJP infection described in this article combined with the known impaired T‐cell function post Bendamustine treatment justifies considering all patients for PJP prophylaxis when they receive Bendamustine treatment. 相似文献
4.
The toxicity and efficacy of the combination bendamustine plus mitoxantrone (BM) was evaluated in 22 patients with advanced chronic lymphocytic leukaemia (CLL). Twenty out of twenty-two patients had received at least one prior regimen. Median age was 71 years (range 53-86). Six out of twenty-two patients were Binet stage B and 16/22 Binet stage C. Bendamustine was given in escalating doses from 80 up to 240 mg/m2 divided in two to three doses per course, mitoxantrone was given as short infusion with 8 up to 10 mg/m2 per course. The number of courses was limited to six and chemotherapy stopped when a complete remission (CR) or partial remission (PR) according to NCI-Criteria was achieved. Haematotoxicity and infection were dose limiting with 4/6 patients suffering from grade 3 infectious complication in the bendamustine level with 240 mg/m2. Six out of twenty-two patients achieved a CR and 13/22 patients a PR resulting in an overall response rate of 86% (19/22 patients). Median time to progression was 10 months (range 4-22) and median survival 39 months (range 6-50). For further studies we recommend a bendamustine dose of 150 mg/m2 combined with 10 mg/m2 mitoxantrone. 相似文献
5.
《Journal of infection and chemotherapy》2022,28(6):810-813
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA is detectable in nasopharyngeal specimens for up to 12–20 days regardless of the presence of chronic diseases in patients. We report a case of prolonged SARS-CoV-2 infection that lasted for more than eight weeks. The patient had persistent lymphopenia after receiving six cycles of bendamustine and rituximab (BR) therapy for follicular lymphoma; the last chemotherapy session was completed nine months before admission. The first nasopharyngeal specimen (NPS) for the SARS-CoV-2 polymerase chain reaction assay tested positive for the N501Y variant five weeks before admission. The patient's general and respiratory conditions gradually worsened; therefore, he was admitted to our hospital, and the same SARS-CoV-2 variant was subsequently identified on admission. Treatment for coronavirus disease was initiated, and the patient's condition improved; however, the NPS tested positive on day 15. The patient was discharged on day 28 and was instructed to isolate at home for a month. Hence, possible prolonged SARS-CoV-2 shedding should be considered in patients who receive BR therapy. 相似文献
6.
Schmidt-Hieber M Busse A Reufi B Knauf W Thiel E Blau IW 《Journal of cancer research and clinical oncology》2009,135(2):227-234
Purpose We investigated the in vitro toxicity of bendamustine and fludarabine to hematopoietic progenitors and stem cells from healthy
donors.
Methods Clonogenic agar colony assays, non-clonogenic long-term liquid cultures (LTC) and apoptosis assays were used to assess the
cytotoxicity of both the agents.
Results Total colony-forming units (CFU) were more sensitive to fludarabine than to bendamustine in agar colony assays (IC50 0.7 μM/L and 8.5 μM/L, respectively). Using the Bliss independence model and combining the two agents yielded additive inhibition
of progenitors. Non-clonogenic assays, including LTC and an apoptosis assay detecting activated caspases showed that stem
cells are characterized by low sensitivity to bendamustine. In contrast, fludarabine strongly inhibited the viability and
growth of stem cells in LTC.
Conclusions Our data show that bendamustine is characterized by lower in vitro toxicity to hematopoietic progenitors and stem cells than
fludarabine and might thus be preferable in regimens prior to stem cells apheresis.
Part of the data has been presented at the annual meeting of the American Association for Cancer Research (AACR) 2005 (Los
Angeles, CA, USA). 相似文献
7.
Pönisch W Mitrou PS Merkle K Herold M Assmann M Wilhelm G Dachselt K Richter P Schirmer V Schulze A Subert R Harksel B Grobe N Stelzer E Schulze M Bittrich A Freund M Pasold R Friedrich T Helbig W Niederwieser D;East German Study Group of Hematology Oncology 《Journal of cancer research and clinical oncology》2006,132(4):205-212
Purpose: This randomized phase III study compared bendamustine and prednisone (BP) to standard melphalan and prednisone (MP) treatment
in previously untreated patients with multiple Myeloma (MM). Patients and Methods: To be included, patients had to have histologically and cytologically proven stage II with progressive diseases or stage
III MM. They were randomly assigned to receive BP (n=68) or MP (n=63). The primary endpoint was the time to treatment failure (TTF). Secondary endpoints included survival, remission rate,
toxicity and quality of life. Results: The overall response rate was 75% in the BP and 70% in the MP group. A significantly higher number of patients treated with
BP achieved a complete remission than did patients receiving MP (32 vs. 13%; P=0.007), and the maximum response was achieved more rapidly in patients treated with BP compared to those receiving MP (6.8
vs. 8.7 cycles; P<0.02). TTF and remission duration were significantly longer in the BP group. Patients receiving BP had higher QoL scores
and reported pain less frequently than patients receiving MP. Conclusion: BP is superior to MP with respect to complete remission rate, TTF, cycles needed to achieve maximum remission and quality
of life and should be considered the new standard in first-line treatment of MM patients not eligible for transplantation. 相似文献
8.
Lissitchkov T Arnaudov G Peytchev D Merkle Kh 《Journal of cancer research and clinical oncology》2006,132(2):99-104
Purpose: Bendamustine hydrochloride, an anti-neoplastic agent with unique mechanism of action, is known to cause impressive remissions
in relapsed nonHodgkin’s lymphoma and chronic lymphocytic leukaemia (CLL). Optimal bendamustine dosing for CLL patients had
not been finally established and a phase I/II study was conducted to determine the maximum tolerated dose (MTD) and dose limiting
toxicity (DLT) of bendamustine. Methods: The open-label, single-centre phase I/II study was conducted from March 2001 to September 2002 in Sofia, Bulgaria. The 15
study patients were extendedly pre-treated, but fludarabine-naive (3 female, 12 male, 47–72 years of age, 61 years on average).
Bendamustine was given at a starting dose of 100 mg/m2 on days 1 and 2 every 3 weeks based on the previous results in lymphoma. Results: Bendamustine was well tolerated in spite of heavy pre-treatment of the study participants. Toxicity corresponded to the
known safety profile of bendamustine, with the exception of bilirubin elevation. The level of 110 mg/m2 was established as MTD. A bendamustine dose of 100 mg/m2 is the recommended dose for further clinical investigations. A 4-week interval is recommended to allow for sufficient recovery.
Efficacy results confirmed powerful anti-neoplastic activity of bendamustine even in extendedly pre-treated CLL patients.
Based on the remission criteria, nine patients were defined as responders (four CRs, two PR, three NC) and two patients as
nonresponders to therapy. Four patients were not evaluable for response, because they had received less than three courses
bendamustine. After a follow-up period of 15 months, the four patients with CR were still in remission. One patient with PR
had relapsed, the other had ongoing response. Conclusions: Bendamustine is a very active and well-tolerated drug in patients with pre-treated and refractory CLL. Fludarabine-naivity
of patients appears to markedly improve their bendamustine tolerability. First-line use of bendamustine is a safe option for
CLL-patients requiring treatment, because bendamustine—owing to its unique pharmacodynamics—(1) is highly effective, (2) reasonably
safe, and (3) does hardly produce cross-resistance against other anti-neoplastic drugs effective in this indication. 相似文献
9.
Bendamustine plus Rituximab Versus R‐CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter,Retrospective Study
下载免费PDF全文
![点击此处可从《The oncologist》网站下载免费的PDF全文](/ch/ext_images/free.gif)
10.
Mathias Rummel Christian Buske Bernd Hertenstein Christian Lerchenmüller Michael Koenigsmann Elisabeth Lange Manfred Reeb Ulrich Kaiser Christina Balser Dirk Behringer Jan Dürig Tobias Gaska Georg Maschmeyer Georg Schliesser Alexander C. Burchardt Juergen Barth Frank Kauff Axel Hinke Richard Greil 《Clinical Lymphoma, Myeloma & Leukemia》2018